An unsolicited offer from Lundbeck threatens to derail Alkermes’ acquisition as competing bids emerge for LUMRYZ maker.
A high-stakes corporate battle is unfolding over Avadel Pharmaceuticals, the maker of LUMRYZ, the first and only once-at-bedtime oxybate treatment for narcolepsy. After initially agreeing to be acquired by Alkermes, Avadel’s board has now declared a competing unsolicited proposal from Danish pharmaceutical company H. Lundbeck A/S to be a “Company Superior Proposal,” setting the stage for potential renegotiations that could reshape the narcolepsy treatment landscape.
The Competing Offers
Lundbeck’s proposal values Avadel at up to $12.43 per share, a significant premium over the original Alkermes transaction. The unsolicited offer has prompted Avadel’s board of directors to formally notify Alkermes that it considers the Lundbeck proposal superior to their existing agreement.
Under the terms of the original transaction agreement with Alkermes, this determination triggers a five-business-day matching period during which Alkermes has the opportunity to negotiate adjustments to its offer. Avadel is required to discuss or negotiate in good faith with Alkermes regarding any proposal to amend the transaction terms so that the Lundbeck offer would no longer constitute a superior proposal.
Implications for Narcolepsy Therapies
The outcome of this corporate battle holds implications for sleep medicine practitioners and their narcolepsy patients. LUMRYZ, which received FDA approval as an extended-release oral suspension for treating cataplexy or excessive daytime sleepiness in patients seven years and older with narcolepsy, is a once-at-bedtime option in oxybate therapy. It aims to address a key challenge patients have faced with traditional twice-nightly oxybate formulations.
Also, earlier this year, Avadel entered into an exclusive global license agreement with XWPharma Ltd to develop and commercialize valiloxybate, a GABA-B receptor agonist, a once-at-bedtime, salt-free, and artificial sweetener-free oxybate formulation. Both acquisition proposals include plans for valiloxybate.
The change in ownership could affect the drugs’ commercialization strategies, pricing, market access, and future development plans. Lundbeck focuses on brain disease drugs and has registered products in more than 80 countries. It does not currently have any drugs with sleep disorder indications. Alkermes’ portfolio of proprietary commercial products focuses on alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Alkermes has been developing drug candidate Alixorexton, an oral, selective orexin 2 receptor agonist for narcolepsy type 1 and type 2 and idiopathic hypersomnia. Different acquirers may bring varying levels of expertise in sleep medicine, different commercial infrastructure for reaching sleep specialists, and divergent strategies for expanding the narcolepsy therapies’ market presence.
Current Transaction Status
Despite Avadel’s board determining that the Lundbeck proposal is superior, the Alkermes transaction agreement remains in full effect. Avadel has not changed its recommendation in support of the Alkermes acquisition at this time.
Following the conclusion of the five-business-day matching period, if Avadel’s board determines in good faith that the Lundbeck proposal continues to constitute a superior offer and that failure to accept it would be inconsistent with the board’s fiduciary duties, Avadel would be entitled to terminate the Alkermes agreement. However, there is no certainty that discussions with Lundbeck will result in a definitive agreement.
Alkermes Response
In a brief statement issued on Friday, Alkermes indicated that its board of directors is considering its options together with advisors. The company emphasized that under the transaction agreement terms, Avadel cannot terminate the agreement to enter into a definitive agreement with Lundbeck without first allowing Alkermes the opportunity to make a counteroffer. Alkermes must be given at least five business days’ notice before Avadel can take action to terminate their agreement.
The pharmaceutical company stated that in the meantime, Avadel must continue to discuss and negotiate in good faith with Alkermes regarding any proposal to amend the transaction agreement. Alkermes indicated it would make further announcements as appropriate.
What’s Next
The timeline for resolution remains uncertain. During the matching period, Avadel and Alkermes are expected to engage in good-faith negotiations. Following this period, Avadel’s board will need to reassess whether the Lundbeck proposal remains superior, taking into account any revised terms Alkermes may offer.
Sleep physicians should monitor this situation closely, as the ultimate acquirer of Avadel could significantly impact their access to narcolepsy therapies, relationships with pharmaceutical representatives, patient assistance programs, and the drug’s long-term development trajectory. The acquisition outcome may also signal broader consolidation trends in the narcolepsy treatment market.
Avadel has stated it will have no further comment on the Lundbeck proposal or potential discussions with Alkermes until the board has completed negotiations during the matching period. Morgan Stanley and Goldman Sachs are serving as financial advisors to Avadel, while J.P. Morgan is advising Alkermes.
We recommend for you:
ID 1709412 © Yakobchuk | Dreamstime.com
